FDA grants fast track designation to IN10018 for ovarian cancer
Click Here to Manage Email Alerts
The FDA granted fast track designation to IN10018 for treatment of platinum-resistant ovarian cancer.
IN10018 (InxMed) is a focal adhesion kinase small molecule inhibitor.
Preclinical and clinical data suggested the agent has promising efficacy when combined with standard chemotherapy for women with platinum-resistant ovarian cancer, according to an InxMed-issued press release.
“[Fast track designation] is an important milestone for InxMed,” Zaiqi Wang, MD, PhD, the company’s chairman and CEO, said in the release. “IN10018 is one of our critical assets to fulfill our ‘best-in-disease combination’ development strategy. We will leverage the advantage of fast track status and work closely with U.S. FDA to speed up further clinical development.”
Read more about
Click Here to Manage Email Alerts